# COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities

> **NCT04860258** · PHASE3 · TERMINATED · sponsor: **CureVac** · enrollment: 129 (actual)

## Conditions studied

- Coronavirus
- Covid19
- SARS-CoV-2
- Severe Acute Respiratory Syndrome

## Interventions

- **BIOLOGICAL:** CVnCoV Vaccine

## Key facts

- **NCT ID:** NCT04860258
- **Lead sponsor:** CureVac
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-22
- **Primary completion:** 2021-09-21
- **Final completion:** 2021-09-21
- **Target enrollment:** 129 (ACTUAL)
- **Why stopped:** The Principal Investigators and CureVac decided to terminate the trial early following a change to the risk/benefit profile.
- **Last updated:** 2022-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04860258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04860258, "COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04860258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*